It has long been shown that CD34+CD38− AML cells are more resistant than the leukemic bulk population to chemotherapeutic agents of the AML backbone chemotherapy (i.e., anthracyclines and cytarabine) [4,5,6]. Here, CD34 is linked to acute myeloid leukemia.